Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant, Inc. has priced an underwritten public offering of its common stock for anticipated gross proceeds of approximately $550 million before underwriting discounts, commissions, and expenses.1 3

The company is offering 26.2 million shares of common stock at an offering price of $21.00 per share.1 2 4 5

The offering is expected to close on or about December 12, 2025, subject to customary closing conditions.1 2 4

Leerink Partners is acting as the sole underwriter for the offering.1 4

Roivant Sciences Ltd., Immunovant’s controlling stockholder, has agreed to purchase shares in the offering.1 2 3 4

Immunovant expects that its existing cash and cash equivalents, together with the proceeds from this offering, will be sufficient to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves’ disease.1 2 3 4

All of the shares in the offering are being sold by Immunovant; this is a primary issuance, not a secondary sale by existing shareholders.1

The shares are being offered pursuant to an automatic shelf registration statement on Form S-3 previously filed with the U.S. Securities and Exchange Commission (SEC).[1 8]

The transaction is part of Immunovant’s strategy to finance the continued clinical development and potential commercialization of its lead FcRn inhibitor candidate IMVT-1402 and broader autoimmune portfolio.1 3

Immunovant characterizes this announcement as containing forward-looking statements, subject to risks detailed in its SEC filings, including the possibility that the offering may not be completed as expected.1